Daphné Dupéré-Richer

Daphné Dupéré-Richer, Ph.D.

Postdoctoral Fellow

Department: MD-HEMATOLOGY/ONCOLOGY-ONCOL
Business Phone: (352) 256-3151
Business Email: daphne@ufl.edu

About Daphné Dupéré-Richer

I obtained a Ph.D. in Experimental Medicine from McGill University in Montréal focusing on mechanisms of resistance to histone deacetylase inhibitors in acute myeloid leukemia. In January 2016, I joined the Licht laboratory. I am interested in understanding how loss of the histone demethylase KDM6A promotes tumorigenesis of multiple myeloma (MM). By the development of isogenic cell lines using CRISPR-mediated engineering, and by using a novel mouse model of MM where KDM6A is loss in the B-cell compartment, I am aiming to elucidate how KDM6A enzyme works and how its loss affects chromatin structure and gene expression.

Publications

2022
Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype.
Molecular cancer therapeutics. 21(4):511-521 [DOI] 10.1158/1535-7163.MCT-21-0216. [PMID] 35086959.
2022
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks.
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(4):756-769 [DOI] 10.1158/1078-0432.CCR-21-2863. [PMID] 34716195.
2022
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.
Cancer discovery. 12(1):186-203 [DOI] 10.1158/2159-8290.CD-20-1771. [PMID] 34417224.
2017
Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Current opinion in hematology. 24(4):336-344 [DOI] 10.1097/MOH.0000000000000358. [PMID] 28441149.
2017
UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Cell reports. 21(3):628-640 [DOI] 10.1016/j.celrep.2017.09.078. [PMID] 29045832.
2016
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.
Advances in cancer research. 131:59-95 [DOI] 10.1016/bs.acr.2016.05.001. [PMID] 27451124.

Grants

Jul 2018 – Jun 2021
KDM6A mutation as an epigenetic driver of multiple myeloma
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC

Contact Details

Phones:
Business:
(352) 256-3151
Emails:
Business:
daphne@ufl.edu
Addresses:
Business Mailing:
PO Box 100276
GAINESVILLE FL 32610
Business Street:
PO BOX 100276
Division of Hematology & Oncology
GAINESVILLE FL 32611